SNY (SNY) Stock Price & Analysis
SNY (SNY) fell 0.02% to USD 43.35 as of July 25, 2026 at 01:47 UTC, according to Nexqual real-time market data.
SNY last closed at USD 43.36; the session ranged USD 42.94–43.48 on volume of 3,060,740 shares. Market capitalization is —, with a 52-week range of USD 40.89–52.68 (NMS). Source: Nexqual, July 25, 2026 at 01:47 UTC.
Key Statistics (as of July 25, 2026 at 01:47 UTC)
| Price | USD 43.35 |
|---|---|
| Change | ▼ 0.02% (down) |
| Previous Close | USD 43.36 |
| Open | USD 43.17 |
| Day Range | USD 42.94 – 43.48 |
| 52-Week Range | USD 40.89 – 52.68 |
| Volume | 3,060,740 shares |
| Market Cap | — |
| Exchange | NMS |
Technical Analysis (SNY)
Nexqual's technical model rates SNY "SELL" based on 1 bullish and 4 bearish signals across 125 daily candles, as of July 25, 2026 at 01:47 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 46.17 (neutral) |
| vs SMA50 | Below (USD 43.41) |
| MACD | 0.11 (positive) |
Analyst Ratings (SNY)
Wall Street analysts rate SNY "Buy" based on 9 analysts, with a mean price target of USD 55.06 (range USD 49–63), per Nexqual as of July 25, 2026 at 01:47 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 9 |
| Mean Target | USD 55.06 |
| High Target | USD 63 |
| Low Target | USD 49 |
| Buy / Hold / Sell | 5 / 5 / 0 |
Earnings (SNY)
| Next Earnings Date | 2026-07-30 |
|---|---|
| EPS Estimate | USD 1.14 |
| Revenue Estimate | $10.90B |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD 1.1 vs est 1.03 ▲ beat |
| 2025-12-31 | USD 0.91 vs est 0.85 ▲ beat |
| 2025-09-30 | USD 1.69 vs est 1.57 ▲ beat |
| 2025-06-30 | USD 0.91 vs est 1 ▼ miss |
Source: Nexqual, July 25, 2026 at 01:47 UTC.
Financials & Fundamentals (SNY)
| Total Revenue | $47.35B |
|---|---|
| Revenue Growth (YoY) | +6.00% |
| Gross Margin | +72.36% |
| Operating Margin | +20.00% |
| Profit Margin | +15.95% |
| ROE | +6.58% |
| Debt / Equity | 27.37 |
| Current Ratio | 1.01 |
| Total Cash | $5.54B |
| Total Debt | $20.02B |
| Free Cash Flow | $16.67B |
Source: Nexqual, July 25, 2026 at 01:47 UTC.
Financial Health Score (SNY)
Nexqual rates SNY's overall financial health "Solid" across five dimensions, as of July 25, 2026 at 01:47 UTC.
| Growth | Solid — Revenue +6% YoY (latest Q) |
|---|---|
| Profitability | Strong — Gross margin 72%, operating 20% |
| Balance Sheet | Strong — $5.54B cash vs $20.0B debt |
| Cash Flow | Strong — FCF $16.7B, 35% margin |
| Efficiency | Mixed — ROE 7%, ROA 4.7% |
Ownership (SNY)
| Insider Ownership | +0.00% |
|---|---|
| Institutional Ownership | +8.87% |
| Float | 2.17B |
| Short % of Float | +0.31% |
Source: Nexqual, July 25, 2026 at 01:47 UTC.
Leadership (SNY)
SNY is led by Belen Garijo Lopez (age 65), CEO & Director, per Nexqual as of July 25, 2026 at 01:47 UTC.
| CEO & Director | Belen Garijo Lopez (age 65) |
|---|---|
| Executive VP & CFO | François-Xavier Roger (age 63) |
| Senior Vice President of Global Diabetes and Senior Vice President of Global Marketing | Pierre Chancel (age 68) |
Major Backers & Investors (SNY)
Notable institutional backers of SNY include Dodge & Cox Inc., Morgan Stanley, Fisher Asset Management, LLC, according to Nexqual as of July 25, 2026 at 01:47 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Dodge & Cox Inc. | 19.78% |
| Morgan Stanley | 4.69% |
| Fisher Asset Management, LLC | 4.29% |
| Bank of America Corporation | 3.56% |
| Franklin Resources, Inc. | 2.69% |
| Invesco | 2.48% |
| Barrow, Hanley Mewhinney & Strauss, LLC | 2.21% |
| JPMorgan | 2.1% |
Source: Nexqual, July 25, 2026 at 01:47 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| GSK | GSK plc | USD 51.35 | ▲ 1.16% |
| NVS | Novartis AG | USD 155.01 | ▲ 1.26% |
| AZN | AstraZeneca PLC | USD 169.26 | ▼ 0.28% |
| RHHBY | Roche Holding Ltd | USD 54.7 | ▲ 5.8% |
| REGN | Regeneron Pharmaceuticals, Inc. | USD 656.01 | ▲ 0.74% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 01:47 UTC. This page is informational and not investment advice.